Introduction

Post-stroke depression (PSD) is a common neuropsychiatric complication of stroke. Generally, PSD is defined as a condition with different degrees of PSD symptoms that persist for more than 2 weeks. The overall incidence rate of PSD is 40%-50%, and the acute period incidence rate is approximately 33%. Although great endeavours have been made over the past decade, unravelling the pathogenesis of PSD still remains a challengeable task. It is widely recognised that PSD is primarily caused by social psychology, neural anatomy, and neurobiology factors. A review has underscored that homocysteine (Hcy) is not only associated with stroke but also with resultant depression. For example, serum levels of total Hcy were observed to be significantly higher in depressed patients than normal controls. Specifically, the degree of depression increased with the increase of total blood Hcy levels.

From a biological viewpoint, Hcy methylation is influenced by several rate-limiting enzymes, and thereof methylenetetrahydrofolate reductase (MTHFR) is a key enzyme. The gene encoding human MTHFR is mapped on chromosome lp36.3, and it includes 11 exons and 10 introns with complementary deoxyribonucleic acid (cDNA) spanning 212 kb. The genomic sequence of MTHFR gene is polymorphic, and one polymorphism in the 4th exon, 677C>T (rs1801133), has been widely evaluated, as its mutation can cause decreased enzyme activity and lead to increased blood Hcy levels consequently. A study found that carriers of MTHFR gene 677T/T genotype had significantly higher levels of blood Hcy than those with the 677C/C genotype. Another study in an elderly population from Norway revealed a close relation between 677T/T genotype and depression. On the basis of above observations, it is reasonable to hypothesise that MTHFR gene 677C>T polymorphism might be involved in the development of PSD. To test this hypothesis, the current study was planned to investigate the association of MTHFR gene 677C>T polymorphism with PSD risk and antidepressant treatment response.
Patients and Methods

This hospital-based case-control association study was conducted at the Department of Neurology and Neurosurgery, the Second Affiliated Hospital of Nanjing Medical University and Nanjing Brain Hospital, China, between February 2010 and December 2014. Approval was obtained from the institutional ethics committee, and written informed consent was obtained from all the subjects.

Stroke was diagnosed by neurologists according to the criteria formulated by the World Health Organisation (WHO), and was further confirmed through magnetic resonance imaging (MRI).

Characteristics of the patients and PSD-free patients were performed using the chi-square test. Hardy-Weinberg equilibrium was used to detect the expected 52% increase in risk of PSD for MTHFR gene 677C>T polymorphism at a two-sided alpha of 0.05. Genomic DNA was obtained from 250µL EDTA-anticoagulated venous blood using a DNA extraction kit (Tiangen Biotech (Beijing) Co., Ltd.) based on the manufacturer's recommendations. The genotypes of MTHFR gene 677C>T polymorphism was determined by polymerase chain reaction (PCR) - restriction fragment length polymorphism (RFLP). Forward and reverse primer sequences were 5'-GGG AAG TGT CTG CGG GAG-3' and 5'-GCC TCA CCT GGA TGG GAA AGA T-3', respectively. PCR reactions were performed in a 25µL volume containing 1 L of 100 ng/ L DNA, 12.5µL 2xTaq Master Mix (Bioer NJing), 2 L primer, and 9.5 L distilled water. DNA was amplified during thermal cycling, which included an initial denaturation at 95°C for 5 minutes, followed by 32 denaturation cycles at 95°C for 30 seconds, annealing at 56.5°C for 40 seconds, and extension at 72°C for 50 seconds, with a final extension at 72°C for 5 minutes. The PCR products were then cut with TaqI (New England Biolabs) at 37°C overnight, and were run in 2% agarose gels at 100 V for 45 minutes.

Comparisons of allele and genotype counts between PSD patients and PSD-free patients were performed using the chi-square test. Hardy-Weinberg equilibrium was used to detect the expected 52% increase in risk of PSD for MTHFR gene 677C>T polymorphism at a two-sided alpha of 0.05. Genomic DNA was obtained from 250µL EDTA-anticoagulated venous blood using a DNA extraction kit (Tiangen Biotech (Beijing) Co., Ltd.) based on the manufacturer's recommendations. The genotypes of MTHFR gene 677C>T polymorphism was determined by polymerase chain reaction (PCR) - restriction fragment length polymorphism (RFLP). Forward and reverse primer sequences were 5'-GGG AAG TGT CTG CGG GAG-3' and 5'-GCC TCA CCT GGA TGG GAA AGA T-3', respectively. PCR reactions were performed in a 25µL volume containing 1 L of 100 ng/ L DNA, 12.5µL 2xTaq Master Mix (Bioer NJing), 2 L primer, and 9.5 L distilled water. DNA was amplified during thermal cycling, which included an initial denaturation at 95°C for 5 minutes, followed by 32 denaturation cycles at 95°C for 30 seconds, annealing at 56.5°C for 40 seconds, and extension at 72°C for 50 seconds, with a final extension at 72°C for 5 minutes. The PCR products were then cut with TaqI (New England Biolabs) at 37°C overnight, and were run in 2% agarose gels at 100 V for 45 minutes.

Results

Of the 292 patients recruited, 11 (3.76%) were lost to follow-up. The overall frequency of mutant 677T allele was estimated to be 39.7% in control groups and the 677T allele was associated with 1.52-fold increased risk of depression. Our current sample had 90.3% power to detect the expected 52% increase in risk of PSD for MTHFR gene 677C>T polymorphism at a two-sided alpha of 0.05.

Table 1: Genotype and allele distributions of MTHFR gene 677C>T polymorphism between patients with and without PSD.

<table>
<thead>
<tr>
<th>Allele or Genotype</th>
<th>PSD patients (n=106)</th>
<th>PSD-free patients (n=175)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
<th>P for HWE</th>
</tr>
</thead>
<tbody>
<tr>
<td>677C</td>
<td>125 (59.1)</td>
<td>253 (72.4)</td>
<td>Reference group</td>
<td>0.59</td>
<td></td>
</tr>
<tr>
<td>677T</td>
<td>87 (40.9)</td>
<td>97 (27.6)</td>
<td>1.82 (1.2772.60)</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>677C/C</td>
<td>25 (23.9)</td>
<td>90 (51.6)</td>
<td>Reference group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>677C/T</td>
<td>75 (70.4)</td>
<td>73 (41.6)</td>
<td>3.65 (2.1176.32)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>677T/T</td>
<td>6 (5.7)</td>
<td>12 (6.8)</td>
<td>1.80 (0.6175.28)</td>
<td>0.61</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: MTHFR, methylenetetrahydrofolate reductase; PSD, post-stroke depression; OR, odds ratio; 95% CI, 95% confidence interval; HWE, Hardy-Weinberg equilibrium.
follow-up. The final analysis involved a total of 281 (96.23%) patients of whom 106 (36.3%) were diagnosed to have PSD, and 175 (59.93%) were free of PSD. Of those diagnosed with PSD, 57 (53.77%) were males and 49 (46.22%) were females having an overall mean age of 62.5 ± 10.4 years. Of the PSD-free patients, 102 (58.25%) were males and 73 (41.71%) were females, having an overall mean age of 63.6 ± 10.2 years. Age and gender were frequency-matched between the two groups (p = 0.54 and p = 0.39). The mean level of HAMD was 26.31 ± 9.33 in PSD patients. Of the PSD patients, 84 (79.2%) were classified as responders and 22 (20.8%) as non-responders after 6-month’s follow-up.

The genotype distributions of MTHFR gene 677C>T polymorphism were in Hardy-Weinberg equilibrium in PSD-free patients (p > 0.05).

Genetic frequencies of this polymorphism and associated risk prediction for PSD were noted (Table-1). The mutant 677T allele of this polymorphism accounted for 87 (40.9%) of PSD patients and 97 (27.6%) of PSD-free patients. The frequencies of 677T/T, 677T/C and 677C/C genotypes were 6 (5.7%), 75 (70.4%) and 25 (23.9%) in PSD patients and 12 (6.8%), 73 (41.6%) and 90 (51.6%) in PSD-free patients. The power to detect allele differences between the two groups was estimated to be 88%. The 677T allele and 677C/C genotype were significantly associated with 1.82-fold (95% CI: 1.27-2.60, p = 0.001) and 3.65-fold (95% CI: 2.11-6.32, p < 0.001) increased risk of PSD relative to the 677C allele and 677C/C genotype, respectively, even after the Bonferroni correction.

There was no detectable significance for the allele and genotype comparisons of MTHFR gene 677C>T polymorphism between responders and non-responders in PSD patients (p > 0.05) (Table-2).

Discussion
Via a candidate gene approach, this association study has identified the mutation of MTHFR gene 677C>T polymorphism to be significantly associated with the increased risk of PSD in Han Chinese, which supports the hypothesis that MTHFR gene is involved in the development of PSD. However, our findings did not support the susceptibility of this polymorphism to antidepressant treatment response after 6-month follow-up. To the best of our knowledge, this is the first report that has interrogated the association between MTHFR gene 677C>T polymorphism and PSD risk.

It is widely recognised that MTHFR is a key enzyme involved in folate metabolism and DNA methylation, and it plays a central role in Hcy homeostasis. Growing evidence indicates that MTHFR genetic defects can lead to hyperhomocysteinemia. Until now, dozens of mutations have been identified in MTHFR gene, and an exonic polymorphism, 677C>T is the widest researched locus. The mutation of this polymorphism can result in the conversion of valine to alanine at codon 222, and is linked to the reduced enzyme activity of MTHFR. In the current literature, the association between MTHFR gene 677C>T polymorphism and depression has been widely evaluated, but it still remains a subject of debate. Some studies have shown that this polymorphism may be causally related to depression. By contrast, a study found no significant association between 677C>T polymorphism and MDD risk in both males and females. Another study also reported that 677C/T genotype, folate deficiency, and Hcy were not associated with cognition or depression in either ethnicity-pooled or stratified analysis. In view of these conflicting findings, we propose that the MTHFR gene-depression relationship may be contingent on the diversities in race and/or region. Extending previous observations, we designed a case-control association study, and for the first time found that the 677T allele and 677C/T genotype were overrepresented in PSD patients and they were associated with the significantly increased risk of having PSD in Han Chinese.

From a biochemical viewpoint, there is evidence that
the rise in blood Hcy levels observed in PSD patients is ascribed to methylation failure of Hcy to methionine due to a supply shortage of methyl groups from methyl folate or lack of vitamin B12 cofactor for this methylation reaction. Methionine is the precursor of S-adenosylmethionine (SAMe), the methyl donor in a host of methylation reactions in the central nervous system involving monoamines and various neurotransmitters. So, increased Hcy levels in depression can serve as an indication of functional folate and/or B12 deficiency, which ultimately cause an imbalance at the monoamine or neurotransmitter level. Thus far, the mechanism underlying the association between MTHFR gene and PSD remains unclear, and it is reasonable to expect that, 677C>T mutation, if involved, can alter Hcy metabolism-related enzyme activity, regulate circulating Hcy levels and ultimately involve in the development of PSD.

Besides, in the present study we have examined the possible association between MTHFR gene 677C>T polymorphism and antidepressant treatment response, yet no hint of significance was attained, in agreement with the findings from a study which reported that this polymorphism did not affect the antidepressant response of fluoxetine treatment. Contrastingly, other studies indicated that MTHFR gene 677C>T polymorphism may have various effects on therapeutic response to different treatments in MDD patients. In addition, the findings of a recent randomised, double-blind, placebo-controlled study using a combination of reduced B-vitamins and micronutrients to treat MDD, supported the Hcy-depression theory and the therapeutic benefits of reduced B vitamins as monotherapy for MDD, especially hinging on the 677C>T genotype. To avoid chance findings due to limited sample sizes of the present study, especially in treatment response analysis, we agree that confirmation in a large, well-designed study is critical.

Finally, several limitations deserve special considerations. First, this study was cross-sectional in design, which precluded addressing the time course of an association between MTHFR gene 677C>T polymorphism and PSD risk, as well as its treatment response. Second, this study was carried out in a monohospital, and generalisation of our findings to the more general population should be interpreted cautiously, as a recent meta-analysis indicated that MTHFR gene 677C>T polymorphism was associated with depression varied across different geographic locations of China. Third, only one polymorphism was genotyped in MTHFR gene, and its contribution to PSD risk and treatment response may be small. Further studies covering the whole MTHFR gene with haplotype tags are required to confirm the involvement of this gene in the development of PSD, and also its interaction with other genes and/or environmental factors is encouraging.

Conclusion
The study provided evidence that the mutation of MTHFR gene 677C>T polymorphism was significantly associated with the increased risk of PSD, but not with antidepressant treatment response in Han Chinese. Additional studies are warranted to replicate our findings as well as elucidate the biological and clinical relevance between MTHFR gene and PSD.

Disclaimer: None.

Conflict of Interest: None.

Source of Funding: This study was partly supported the Scientific Research Project of Jiangsu Province Department of Health, Key Project of Nanjing Medical University.

References
11. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal


